FNCH News and Press, Finch Therapeutics Group Inc. From 12/23/21

Shares of Finch Therapeutics (FNCH +10.1%) are on the rise today after a director of the company and venture capital investor bought additional shares. Nicolas Haft, managing director of OMX Ventures, bought 63,850 shares at $10.18 on Dec. 20 according to an SEC filing. Following the transact...

Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...

The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Me...

Seth Klarman’s 13F portfolio value decreased from $12.33B to $10.88B this quarter. Baupost Group increased Liberty SiriusXM, Theravance Biopharma, and Joby Aviation while decreasing eBay, Willis Towers Watson, International Flavors & Fragrances, and PG&E. The portfo...

SOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...

Finch Therapeutics (NASDAQ:FNCH): Q3 GAAP EPS of -$0.21 beats by $0.07. Revenue of $11.34M, compared to $1.77M a year ago. Cash and cash equivalents as of September 30, 2021 was $149.2M Press Release For further details see: Finch Therapeutics EPS beats by $0.07

New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data presented at ACG annual meeting ...

Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the company Debra Silberg, MD, PhD to transition from clinical advisor to interim CMO SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, ...

New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported data Aggregated 88.2% sustained clinical cure ra...

New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in int...